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Abstract
Circulating plasmacytoid dendritic cells (pDC) decline during HIV-1 infection, but at the same time they express markedly
higher levels of interferon alpha (IFNa), which is associated with HIV-1 disease progression. Here we show an accumulation
of pDC in lymph nodes (LN) of treatment-naı ¨ve HIV-1 patients. This phenomenon was associated with elevated expression
of the LN homing marker, CCR7, on pDC in peripheral blood of HIV-1 patients, which conferred increased migratory capacity
in response to CCR7 ligands in ex vivo functional assays. LN-homed pDC of HIV-1 patients presented higher CD40 and lower
BDCA2 levels, but unchanged CD83 and CD86 expression. In addition, these cells expressed markedly higher amounts of
IFNa compared to uninfected individuals, and were undergoing faster rates of cell death. These results demonstrate for the
first time that in asymptomatic, untreated HIV-1 patients circulating pDC up-regulate CCR7 expression, accumulate in lymph
nodes, and express high amounts of IFNa before undergoing cell death. Since IFNa inhibits cell proliferation and modulates
immune responses, chronically high levels of this cytokine in LN of HIV-1 patients may impair differentiation and immune
function of bystander CD4
+ T cells, thus playing into the mechanisms of AIDS immunopathogenesis.
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Introduction
Untreated HIV-1 infection is characterized by a progressive
decline of CD4
+ T cell number and function. Recent studies have
shown that CD4
+ T cells are rapidly depleted from the gut-
associated lymphoid tissue (GALT) and other mucosal sites within
the first few weeks of infection (for a comprehensive review see
[1]). Mucosal depletion of CD4
+ T cells is followed by the onset of
generalized immune activation and progressive loss of immune
function, which are manifested throughout the asymptomatic
chronic phase of the disease [1]. The level of immune activation in
HIV-1 infected subjects is a strong independent predictor for HIV-
1 disease progression [2,3,4,5,6]. However, the mechanisms that
trigger and drive persistent immune activation remain to be
elucidated.
Interferon alpha (IFNa) is rapidly upregulated in response to
viral infections [7,8,9], and is an essential player in antiviral
immune responses: it induces the expression of cellular genes that
interfere with viral replication, activates NK cell function, and
promotes maturation of antigen presenting cells [10,11,12,13,14].
Plasmacytoid dendritic cells (pDC) are the main IFNa producers
in humans [15].
The role of pDC and IFNa during HIV-1 infection has been a
matter of intense debate. Indeed, HIV-1 disease progression is
associated with a decline of pDC from the peripheral compart-
ment, which correlates with high viral load and reduced CD4
counts [16]. In addition, pDC of HIV-1 patients produce lower
levels of IFNa when challenged ex vivo with reference viruses
[16,17,18,19,20,21,22]. On the other hand, several studies have
documented the chronic production of IFNa in HIV-1 patients,
which is associated with disease progression [23,24,25,26]. Our
and other groups showed that increased IFNa expression
correlates with HIV-1/SIV disease progression [27,28,29]. In
particular, we showed that a specific subtype of IFNa – namely
IFNa2b – is preferentially up-regulated in HIV-1 patients
throughout the course of the disease [30]. Moreover, we
demonstrated that – despite their decline – residual pDC in
peripheral blood of HIV-1 patients express IFNa at levels
markedly higher than pDC of healthy controls [28]. Recent
studies have suggested that IFNa may play a role in driving
immune activation during HIV-1 infection. Siliciano and
colleagues reported the up-regulation of type I interferon-
regulated genes – including cell cycle-associated genes – in
activated CD4+ T cells of HIV-1 patients [31]. Moreover, IFNa
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+ T cells [32],
and gene expression profiles suggest that exposure to IFNa may
induce chronic activation of CD4
+ T cells [31]. Evidence for a
possible role of pDC and IFNa in AIDS pathogenesis also comes
from animal models. Persistent decline of circulating pDC and
chronic over-expression of IFNa are observed during pathogenic
SIV infection of non-natural hosts [33,34], but not during non-
pathogenic SIV infection of natural hosts [29,35]. These reports
suggest that IFNa may play a role involved in promoting chronic
activation and immune dysfunction during HIV-1 disease.
Although various hypotheses have been called into play
[19,36,37,38,39,40], one key aspect that remains to be elucidated
is whether the decline of pDC observed in peripheral blood of
HIV-1 patients reflects systemic depletion or relocation to other
body compartments. Thus, in the present study we investigated the
fate and function of pDC in HIV-1 infection. We analyzed the
expression of tissue homing markers on circulating pDC from
HIV-1 patients and control individuals. Further, we analyzed
frequency, maturation stage, steady-state IFNa secretion, and cell
death rate of pDC in lymph nodes of HIV-1 patients and healthy
subjects. Our results show that circulating pDC of HIV-1 patients
relocate to lymphoid tissues and express high levels of IFNa before
undergoing cell death.
Materials and Methods
Patients
All samples were obtained with signed informed consent after
approval from the Institutional Review Boards of the University of
Maryland, Baltimore and University of Hamburg, Germany, and
according to ethical guidelines. Lymph nodes (cervical and
axillary) and peripheral blood were obtained from HIV-1 patients
and uninfected controls at the University of Hamburg-Eppendorf,
Germany, at the University of Maryland School of Medicine, at
the University of Maryland Medical Center, and at the National
Disease Resource Interchange Program (Philadelphia, PA).
Lymph nodes were placed in sterile saline immediately after
excision, and mononuclear cells were dissociated mechanically.
Peripheral blood and lymph node mononuclear cells (PBMC and
LNMC) were isolated by Ficoll centrifugation. Frozen PBMC and
LNMC samples were thawed and analyzed all at the same time at
the Institute of Human Virology (Baltimore, MD). To ensure
reliability of the functional measures carried out with cryopre-
served samples – including the exclusion of samples that presented
$25% of dead cells by trypan blue exclusion upon thawing – we
followed guidelines reported in several studies published previously
[41,42,43,44].
Flow Cytometry
For surface staining, PBMC and LNMC suspensions were
incubated in the dark for 30 minutes at 4uC with anti-CD123 and
-BDCA2 or -BDCA4 antibodies (Miltenyi Biotec, Auburn, CA) to
identify pDC, in combination with anti-CCR4, -CCR7, -CCR9,
-CD18, -CD29, -CD40, -CD49d, -CD83, -CD86, -CD62L,
-CD103, -Integrin b7, or Annexin V (all from BD Biosciences,
San Jose, CA). As control, we used isotype-matched antibodies
labeled with the appropriate fluorochrome (BD Biosciences). After
staining, cells were washed with phosphate buffer saline (PBS) and
analyzed by flow cytometry (FACSCalibur) using CellQuest
software (both from BD Biosciences). In all cases, 10
6 events were
acquired corresponding to live mononuclear cells as assessed by
forward and side light scatter profile. Steady state IFNa secretion
was assayed using the IFNa Secretion and Detection Kit (Miltenyi
Biotech). Briefly, immediately after thawing LNMC were
incubated with an anti-IFNa Catch Reagent (anti-IFNa antibody
conjugated to a proprietary cell surface-specific monoclonal
antibody). After a 20-minute incubation to allow IFNa secretion
and capture by the Catch Reagent, the cells were incubated with
an IFNa Detection Reagent (PE-labeled anti-IFNa antibody)
along with antibodies to CD123 and BDCA2 to identify pDC by
flow cytometry. Expression of the homing markers, staining with
Annexin V and IFNa secretion were determined as Geometric
Mean Fluorescence Intensity (GMFI) by gating on the live cell
population (as assessed by forward and side scatter light profile)
and on the pDC population (as assessed by BDCA2/4
+CD123
+).
Data analysis was performed with the FlowJo software (Tree Star,
Ashland, OR).
Migration Assays
Evaluation of migratory properties of pDC from peripheral
blood of HIV-1 positive and negative subjects was performed
using a modified transmigration assay [45]. This assay utilized
unfractionated PBMC, thereby avoiding unintentional in vitro
maturation effects during purification, and increased total input
PBMC concentration to account for decreased frequencies of
dendritic cells in PBMC of HIV-1 patients. Briefly, CCL19
(MIP3b) and CCL21 (SLC) (R & D Systems, Minneapolis, MN)
were diluted to 100 ng/ml each in RPMI 1640 supplemented with
10% human serum AB, and added (alone or in combination) in
the lower chamber of a 24-well Costar transwell plate (Corning
Inc., Lowell, MA). Media without chemokine was used as control.
PBMC were placed at 2610
7 cells/ml in RPMI plus 10% human
serum AB, 100 ml( 2 610
6 cells) were added to the upper chamber
and incubated for 2 hours at 37uCi n5 %C O 2. Cells in the bottom
wells were then harvested by pipetting, and residual cells were
collected by rinsing the underside of the filter with 10 mM EDTA
in PBS. Cells were washed and stained with the appropriate
antibodies, and analyzed by flow cytometry. Duplicate results were
averaged. Net migration was defined as the percentage of pDC
migrating in response to chemokines minus the percent migrating
in media alone.
Real-time PCR Quantification of HIV-1 DNA
Total cellular DNA was extracted from 1610
6 LNMC using the
DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). DNA was
analyzed by real-time quantitative PCR using a Bio-Rad iQ5
Real-Time PCR system with iQSYBR green supermix (Bio-Rad,
Hercules, CA). Reactions were performed in triplicate in parallel
with sets of known quantitative standards for HIV-1 DNA and
albumin. HIV-1 DNA was quantified using the following primers
59-GGCTAACTAGGGAACCCACTG-39 (sense) and 59-CT-
GCTAGAGATTTTCCACACTGAC-39 (antisense). PCR was
performed for 2 min at 95uC followed by 40 cycles of 30 sec at
95uC and 30 sec at 60uC. Cell number was determined using
albumin as a reference with the following primers 59-
TGTTGCATGAGAAAACGCCA-39 (sense) and 59-GTCG-
CCTGTTCACCAAGGAT-39 (antisense). PCR was performed
for 2 min at 95uC followed by 40 cycles of 30 sec at 95uC and
1 min at 62uC. The viral load was expressed as percent of CD4
+ T
cells harboring HIV-1 genome.
Statistical Analyses
Data were analyzed with Wilcoxon rank-sum test. Spearman’s r
was used to describe correlations. All statistical analyses assumed a
2-sided significance level of 0.05. Data were summarized using
Median and Interquartile Range (IQR) or Mean 6 Standard
Error of Means (SEM), as indicated in the tables and figure
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Results
Accumulation of pDC in lymph nodes of HIV-1 patients
Recent studies strongly suggest that chronic, exacerbated IFNa
expression may be a cofactor in the immunopathogenesis of HIV-
1 disease [29,31]. As upon virus infection pDC are the main IFNa
producers, a better understanding of their fate and function during
HIV-1 infection may help elucidate the mechanisms of immune
dysfunction. Previous studies showed a decline of pDC in
peripheral blood of HIV-1 patients [18,28]. Thus, we sought to
assess whether this observation could be explained with relocation
to lymph nodes. To that end, we obtained lymph node samples
from HIV-1 patients (n=18) and healthy controls (n=11), whose
demographic and clinical characteristics are shown in Table 1.
The median age (and interquartile range, IQR) of HIV-1 positive
individuals at time of sample collection was 31 years (26–35) and
100% were male Caucasians. The median age for uninfected
individuals was 50 years (26–61), 73% were male, and 81% were
Caucasians. HIV-1 patients had a median CD4
+ T cell count of
413 cells/ml (348–538), median viremia of 4.5 log10 copies of HIV-
1 RNA per ml of blood (3.7–5.3), while we determined that a
median 1.3% of CD4
+ T cells in lymph node mononuclear cells
carried proviral HIV-1 DNA (0.2–1.5). All HIV-1 patients were off
therapy at the time of sample collection. In addition, as indicated
in Materials and Methods, we followed previously described
guidelines – e.g. the exclusion of samples with $25% of dead cells
by trypan blue exclusion upon thawing – so as to ensure the
reliability of studies carried out with cryopreserved samples
[41,42,43,44].
We analyzed the frequency of pDC in lymph node mononu-
clear cells (LNMC). Figure 1A reports two flow cytometry plots
representative of a healthy control (top plot) and an HIV-1 positive
individual (bottom plot), while Figure 1B shows the summary
results for all individuals in each study group (black bar: controls;
white bar: HIV-1 patients). Our results show a significant increase
in the percentage of lymph node-homed pDC in HIV-1 patients
compared to healthy controls (p=0.002). Indeed, the mean
percentage of pDC in LNMC of HIV-1 infected patients was
0.8760.08 vs. 0.4560.05 in control individuals. Moreover, when
HIV-1 patients were stratified around the median value of the
HIV-1 viral load (4.5 log10 copies/ml), the difference in the
percentage of LN-homed pDC between control individuals and
HIV-1 patients with viremia .4.5 log10 copies/ml was even more
remarkable (p=0.001; Figure 1B; upward diagonal bar). No
statistically significant difference was observed between HIV-1
patients with viremia .4.5 log10 and ,4.5 log10 copies/ml
(p.0.05). These results suggest that in HIV-1 positive individuals
circulating pDC relocate from the peripheral blood to lymph
nodes, possibly in response to undergoing viral replication. It is
also important to underscore that for these and all the other results
reported below, all samples were analyzed concurrently, side by
side to ensure reproducibility of the data.
Increased expression of the lymph node homing markers
CCR7 and CD62L, and GALT homing marker CD103 on
circulating pDC of HIV-1 patients
In an attempt to elucidate the mechanisms involved in the
accumulation of pDC in lymph nodes of HIV-1 patients, we
investigated the expression of lymph node and other tissue homing
markers on circulating pDC of 17 HIV-1 positive and 11
uninfected individuals in a cross sectional study.
Table 2 reports the demographic and clinical parameters of the
peripheral blood donors. The median age (and IQR) of HIV-1-
infected individuals at time of sample collection was 41 years (36–
51) and ,70% were male African American, while for uninfected
individuals was 37 years (31–39), 55% were male, and 64% were
Caucasians. For HIV-1 positive subjects, the median absolute
CD4
+ T cell count (and IQR) was 402 cells/ml (294–530), and the
median HIV-1 RNA copies/ml blood was 3.7 log10 (1.7–4.7). The
percentage of pDC in PBMC of HIV-1 positive individuals was
markedly reduced compared to negative controls: 0.2560.04 vs.
0.5760.07; p=0.003. About two thirds of the HIV-1 patients were
Table 1. Demographic and clinical parameters of lymph node
donors.
Characteristic
HIV-1 positive
(n=18)
Controls
(n=11)
Age 31 (26–35) 50 (26–61)
Gender (Male: Female) 18:0 8:3
Ethnicity (Cauc. : Afr. Amer. : Hisp.) 18:0:0 9:1:1
CD4
+ T cells/ml 413 (348–538) n.a.
Percent pDC in total LNMC 0.8760.08 0.4560.05
Log10 HIV-1 RNA copies/ml blood 4.5 (3.7–5.3) N/A
Percent HIV-1
+ CD4
+ T cells in LN 1.3 (0.2–1.5) N/A
ART status (On: Off) 0:18 N/A
All data are Median (Interquartile Range) except for % pDC in total LNMC, which
is Mean 6 Standard Error of Means; n.a. =not available; N/A=not applicable;
LNMC=lymph node mononuclear cells; ART=Antiretroviral therapy.
doi:10.1371/journal.pone.0011110.t001
Figure 1. Accumulation of pDC in lymph nodes of HIV-1
patients. Panel A: flow cytometry plots showing the pDC population in
lymph node mononuclear cells (LNMC) of a representative control
individual (top) and HIV-1 patient (bottom). We identified pDC by
staining whole LNMC with anti-BDCA2 and anti-CD123 antibodies
(rectangles within density plots) and by gating onto the live cell
population as assessed by forward and side light scatter profile (not
shown). Panel B: summary results for the frequency of pDC in LNMC of
healthy controls (black bar, n=11) and HIV-1 patients (white bar: total
patients, n=18; downward diagonal bar: patients with ,4.5 log10
copies/ml HIV-1 RNA, n=9; upward diagonal bar: patients with .4.5
log10 copies/ml HIV-1 RNA, n=9). The panel shows the Mean and SEM
values of pDC frequencies for each study group.
doi:10.1371/journal.pone.0011110.g001
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described previously, the decline in pDC frequency correlated
inversely with HIV-1 viremia (p=0.01, r=20.7; data not shown)
[28].
To assess whether accumulation of pDC in LN of HIV-1
infected patients involved modulation of tissue homing markers,
we analyzed the expression of several cell surface receptors on
circulating pDC of HIV-1 positive and negative individuals. The
markers we analyzed included: CD62L and CCR7 (lymph nodes);
CCR4 (skin); CD18, CD29 (inflamed tissues); CD49d, CD103,
CCR9, and integrin b7( lamina propria and intraepithelial sites of
the gut associated lymphoid tissue or GALT). Figure 2A shows
representative flow cytometry plots obtained by staining PBMC
from a representative healthy control (top density plot and gray
area histogram plots) and an HIV-1 patient (bottom density plot
and black line histogram plots) with antibodies directed to BDCA4
and CD123 (to identify pDC) in conjunction with antibodies
against homing markers of interest. Table 3 summarized the
results of our analyses for all HIV-1 patients and control
individuals, and reports the p value determined with the
nonparametric Wilcoxon rank-sum test. The data are expressed
as the Mean (6 SEM) of the Geometric Mean Fluorescence
Intensity (GMFI) values for each cell surface marker determined
by flow cytometry with cells from all individuals in the two study
groups. As shown in the table, among all the markers analyzed,
pDC of HIV-1 patients displayed a statistically significant
upregulation of only three markers: CCR7, CD62L, and CD103
(CCR7: p,0.05, CD62L: p,0.05, CD103: p,0.01; see Table 3
and Figures 2B). The mean CCR7, CD62L and CD103 GMFI 6
SEM in HIV-1 positive vs. negative individuals were: 101.2629.3
vs. 47.566.3; 292.4631.1 vs. 178.4633.2; and 20.764.6 vs.
11.261.2, respectively. All other homing markers (CCR4, CD49d,
integrin b7, CCR9, CD18 and CD29) did not show any
statistically significant difference between the two study groups
(p.0.05; see Table 3 and Figure 2A).
Interestingly, Figure 2C shows that CCR7 expression was
higher on pDC of viremic than aviremic patients: it correlated
inversely with their frequency in peripheral blood (p=0.008, r=
-0.6), and correlated directly with HIV-1 viremia (p,0.001,
r=0.79). Importantly, the line summarizing the data in Figure 2C
uses a linear model fitted on the logarithmic scale that expresses
HIV-1 viremia. Altogether, these results suggest that ongoing
HIV-1 replication drives upregulation of CCR7 on pDC of HIV-1
patients. Thus, higher expression of CCR7 and CD62L might
promote their relocation from peripheral blood to lymph nodes,
which are the site of chronic viral replication.
Increased migration of pDC from HIV-1 patients in
response to CCR7 ligands
To determine whether higher CCR7 expression on pDC from
peripheral blood of HIV-1 patients could mediate their migration
from the blood to lymphoid organs, we used a transwell migration
assay to determine the ability of pDC from a subset of HIV-1
positive (n=11) and negative (n=6) individuals to migrate in
response to the CCR7 ligands, CCL19 and 21. Since CCR7
expression was found to correlate with HIV-1 viremia, the patients
were divided into two groups: those with detectable (.50 copies/
ml, off ART; n=6) and those with undetectable HIV-1 RNA (,50
copies/ml, on ART; n=5).
We observed that the net migration of pDC to CCL19 and 21
in HIV-1 positive individuals with detectable viral load was
significantly greater than that of pDC from HIV-1 negative and
positive individuals with undetectable viral load (p,0.01,
Figure 3A). The migration index correlated directly with CCR7
expression on pDC (p=0.01, r=0.7; Figure 3B). Moreover, we
found that the migration index of pDC correlated inversely with
their frequency in PBMC (p=0.04, r=20.69; Figure 3C), and
directly with HIV-1 viremia (p=0.01, r=0.7; Figure 3D).
We conclude that CCR7 upregulation on pDC of HIV-1
patients translates into an increased migratory potential in ex vivo
assays. These results are in agreement with the ones described
above, and further support the possibility that decreased pDC
numbers in peripheral blood are due to relocation to lymph nodes.
Abnormal cell surface marker expression profile and
increased IFNa expression in lymph node-homed pDC of
HIV-1 patients
Previous studies showed that pDC isolated from peripheral
blood of HIV-1 patients produced lower levels of IFNa upon ex
vivo stimulation with reference viruses, which was initially
attributed to a functional defect of these cells due HIV-1 infection
[17,46]. However, subsequent studies demonstrated that in vitro
stimulation does not faithfully reflect the ability of pDC to produce
IFNa in vivo [47]. Indeed, we have demonstrated that circulating
pDC of HIV-1 patients express markedly higher levels of IFNa
mRNA and protein [28]. To address the possibility that chronic
HIV-1 replication in lymph nodes may affect the activation,
maturation and function of pDC, we analyzed these cells by flow
cytometry for the expression of the activation and maturation
markers CD40, BCDA2, CD83 and CD86, as well as the steady
state IFNa secretion [38,48,49,50].
Whole LNMC preparations were stained with antibodies
directed to BDCA2 and CD123 (to identify the pDC population;
Figure 4A; top panel: healthy control; bottom panel: HIV-1
patient) in combination with antibodies directed to CD40, CD83
or CD86. Figure 4 shows representative flow cytometry histogram
plots obtained by staining LNMC from a healthy control (gray
area) and an HIV-1 patient (black line) with anti-CD40 (panel B),
-BDCA2 (panel D), -CD83 (panel F), and -CD86 (panel H)
antibodies, respectively. Summary results shown in Figure 4C
demonstrate that CD40 expression was significantly upregulated
on pDC of HIV-1 patients (white bar) compared to healthy
subjects (black bar; p,0.0001). The mean GMFI 6 SEM was
26.263.5 for HIV-1 patients vs. 7.861.3 for uninfected persons
(Table 4). In addition, Figure 4E shows that BDCA2 expression
was significantly lower on pDC of HIV-1 patients (p,0.03): the
mean GMFI 6 SEM was 206.2620.8 vs. 462.5685.9 for controls
Table 2. Demographic and clinical parameters of peripheral
blood donors.
Characteristic
HIV-1 positive
(n=17)
Controls
(n=11)
Age 41 (36–51) 36 (31–39)
Gender (Male: Female) 12:5 6:5
Ethnicity (Cauc. : Afr. Amer. : Hisp.) 4:13:0 7:2:2
CD4
+ T cells/ml of blood 402 (294–530) n.a.
Percent of pDC in total PBMC 0.2560.04 0.5760.07
Log10 HIV-1 RNA copies/ml blood 3.7 (1.7–4.7) N/A
ART status (On: Off) 6:11 N/A
All data are Median (Interquartile Range) except for % pDC in total PBMC, which
is Mean 6 Standard Error of Means; n.a. =not available; N/A=not applicable;
PBMC=peripheral blood mononuclear cells; ART=Antiretroviral therapy.
doi:10.1371/journal.pone.0011110.t002
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PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11110Figure 2. Increased expression of lymphoid tissue homing markers on circulating pDC of HIV-1 positive versus negative
individuals. Panel A: representative flow cytometry plots showing expression of nine homing markers grouped by tissue specificity: CD62L and
CCR7 (lymph nodes); CCR4 (skin); CD18 and CD29 (inflamed tissues); and CD49d, CD103, CCR9 and integrin b7 (GALT). Histogram plots were obtained
by gating onto the live cell population as assessed by forward and side light scatter profile (not shown), and then onto the pDC population as
identified by staining with anti-BDCA4 and anti-CD123 antibodies (rectangles within density plots). Top density plot and gray area histogram: healthy
control; bottom density plot and black line histogram: HIV-1 patient. Panel B: summary results of CCR7, CD62L and CD103 expression on pDC of HIV-1
positive (n=17) and negative individuals (n=11). We assessed the Geometric Mean Fluorescence Intensity (GMFI) for each marker by flow cytometry
(Materials and Methods). The panels show the Mean and SEM of the GMFI values determined for all individuals in the two study groups. Black bars:
healthy controls; white bar: HIV-1 patients. Panel C: correlation analyses between CCR7 expression and frequency of pDC in PBMC of HIV-1 patients
(left) and HIV-1 viremia (right). The line summarizing the data uses a linear model fitted on the logarithmic scale that expresses HIV-1 viremia. Closed
circles (N): viremic patients; closed diamonds (X): aviremic patients.
doi:10.1371/journal.pone.0011110.g002
IFNa Expression in HIV/AIDS
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11110(Table 4). However, we found no difference (p.0.05) in the
expression levels of CD83 and CD86 between HIV-1 patients and
healthy controls: 99.7626.5 vs. 77.8634.6; and 14.762.4 vs.
9.962.3 (Figure 4G and 4I; Table 4). The increase in CD40
expression did not correlate with proviral HIV-1 DNA content
(r=0.4, p.0.05), but correlated directly with HIV-1 viremia
(r=0.62, p=0.02; (data not shown).
Next we analyzed baseline IFNa secretion by pDC using a flow
cytometry-based assay that detects the cytokine following secretion
by the producer cell. Pilot experiments showed that IFNa
secretion under our assay conditions is unaffected by the process
of cell freezing and thawing (not shown). Figure 5A shows
representative results obtained with cells from a healthy control
(top density plot and gray area histogram plot) and an HIV-1
patient (bottom density plot and black line histogram plot). The
summary results for all individuals in each study group show that
unstimulated pDC of HIV-1 patients (white bar) secrete
significantly higher amounts of IFNa compared to control
individuals (black bar; p=0.01): the mean GMFI 6 SEM for
the two study groups was 66.7611.3 vs. 40.068.9, respectively
(Figure 5B and Table 4). These results demonstrate that lymph
node-homed pDC of HIV-1 patients present activated but
immature phenotype, and secrete elevated amounts of IFNa.
Lymph node-homed pDC of HIV-1 patients undergo
apoptosis at higher rate
As shown above, our results indicate that the decline of
circulating pDC in HIV-1 patients is associated with increased
expression of functional lymph node homing markers. We also
found increased frequencies of pDC in lymph nodes of HIV-1
patients, particularly those with higher viral loads. Next, we sought
to determine whether there might be underlying mechanisms that
compensate the migration of pDC to lymph nodes in HIV-1
patients, thereby offsetting in part accumulation of these cells.
A potential mechanism involved in this phenomenon could be a
higher rate of pDC death after relocation to lymph nodes [33].
Therefore, uncultured, non-stimulated LNMC from HIV-1
patients and controls were stained with antibodies directed to
BDCA2 and CD123 (to identify the pDC population) in
combination with Annexin V, which allows the identification of
cells undergoing apoptosis. As shown in Figure 6B, the mean
percentage of Annexin V positive pDC (6 SEM) was significantly
higher for HIV-1 positive (white bar) than negative individuals
(black bar; p=0.01): 15.561.5 vs. 8.961.9 (Table 4). Figure 6A
shows plots representative of a healthy control (top density plot
and gray area histogram plot) and an HIV-1 patient (bottom
density plot and black line histogram plot). Since cells from HIV-1
positive individuals are more susceptible to apoptosis and may be
lost at a higher rate during the freezing-thawing process compared
to cells of healthy individuals, it is conceivable that the higher
frequency of Annexin V-positive pDC in HIV-1 patients may be
somewhat underestimated.
Correlation analyses
Based upon our nonparametric correlation analyses, IFNa
secretion was not associated with pDC frequency in LNMC,
CD40 expression on lymph node-homed pDC, HIV-1 proviral
DNA in lymph nodes, or HIV-1 blood viremia (p.0.05; data not
shown). A possible explanation for these results – which is further
addressed in the Discussion – is that pDC express IFNa in
response to HIV-1 virions and/or proteins trapped in the
intercellular space in lymph nodes. In addition, while we did not
find any significant correlation between Annexin V staining and
HIV-1 proviral DNA (data not shown), Annexin V staining
correlated significantly with the frequency of pDC in lymph nodes
(r=0.54, p=0.01; Figure 7A), IFNa secretion by pDC in lymph
nodes (r=0.48, p=0.04; Figure 7B), and HIV-1 blood viremia
(r=0.57, p=0.01; Figure 7C).
Altogether, the results presented in this report demonstrate that
during HIV-1 infection pDC relocate to lymph nodes and secrete
higher amounts of IFNa than their counterparts in uninfected
individuals. Concurrently, pDC undergo cell death at significantly
higher rate, which may in part offset their accumulation in lymph
nodes.
Discussion
In the present report we investigated fate, activation, matura-
tion, and function of plasmacytoid dendritic cells (pDC) during
HIV-1 disease. Since most of the HIV-1 positive blood donors and
all LN donors enrolled in our study were treatment-naı ¨ve at time
of sample collection, the effects of anti-retroviral therapy on viral
replication, immune cell distribution, activation and function are
not expected to influence significantly our results.
The fate of pDC in the course of HIV-1 infection has been a
matter of intense debate. Soon after the identification of
CD4
+Lin
–CD11c
–BDCA2/4
+CD123
+ plasmacytoid dendritic
cells as the major IFNa-producing cell type in humans upon
Table 3. Expression of homing markers on peripheral blood pDC.
Target Tissue Homing marker HIV-1 patients (n=17) Controls (n=11) p values
Lymph nodes CCR7 101.2629.3 47.566.3 ,0.05
CD62L 292.4631.1 178.4633.2 ,0.05
Gut associated lymphoid
tissue
CD49d 695.16104.6 894.96154.2 .0.05
CD103 20.764.6 11.261.2 ,0.01
CCR9 14.461.3 15.360.9 .0.05
Integrin b7 245.3640.3 213.9618.3 .0.05
Inflamed tissues CD18 54.4616.4 40.3613.5 .0.05
CD29 676.7687.9 559.66218.5 .0.05
Skin CCR4 138.5622.4 88.1620.5 .0.05
All data are Mean 6 Standard Error of Means of the Geometric Mean Fluorescence Intensity (GMFI) values determined for all individuals in each study group.
doi:10.1371/journal.pone.0011110.t003
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of pDC in peripheral blood of HIV-1 patients [16,18,19]. These
results were attributed to depletion following direct virus infection
[19,36,37]. However, subsequent studies suggested that the decline
of pDC in peripheral blood does not reflect a systemic depletion of
these cells [28,38,39], and may involve relocation to lymphoid
tissues, but failed to provide a mechanism that could explain the
observations [38]. The present report shows for the first time that
pDC accumulate in lymph nodes of HIV-1 patients, particularly
those with highest viral loads. A recent study by Panda et al.
showed that circulating pDC decline substantially in older
compared to younger individuals [51]. In our study, there was
no statistically significant difference in the median age of
uninfected and infected blood donors. Therefore, age was not a
factor in the decline in circulating pDC in HIV-1 infected
individuals compared to healthy controls. As indicated in the
Materials and Methods, the studies described in the present report
were carried out with cryopreserved cell preparations. In order for
the freezing-thawing process to account for the depletion or
accumulation of pDC in peripheral blood or lymph nodes,
respectively, of HIV-1 patients vs. control individuals that we
describe here, one would have to postulate that: a) to explain a
selective change in pDC frequency compared to other cells
populations (T cells, B cells, NK cells, myeloid cells, etc), pDC
would have to be affected by freezing-thawing differently than
other cell types present in the preparations being analyzed; and b)
to explain a selective depletion of pDC in peripheral blood and a
selective accumulation in lymph nodes, pDC would have to be
affected by freezing-thawing in opposite fashion in PBMC vs.
LNMC preparations. While it is conceivable that freezing-thawing
may kill cells from viremic HIV-1 patients more than cells from
aviremic patients or healthy individuals, we believe the postulates
Figure 3. Higher migratory potential of circulating pDC from HIV-1 positive versus negative individuals in response to CCR7
ligands (CCL19 and CCL21). Panel A: migration index of circulating pDC in response to CCR7 ligands. Total PBMC were seeded in the upper
chamber of a transwell plate, while medium containing CCL19 and CCL21 (alone and in combination) was placed in the lower chamber. Flow
cytometry was used to score pDC found in the lower chamber in response to CCR7 ligands vs. medium alone. The figure shows Migration Indices
(determined as described in Materials and Methods) for control individuals (black bars; n=6) vs. aviremic HIV-1 patients (,50 copies/ml of HIV-1 RNA;
gray bars; n=5) vs. viremic patients (.50 copies/ml of HIV-1 RNA; white bars; n=6). 19: treatment with CCL19; 21: treatment with CCL21; 19+21:
treatment with CCL19 and CCL21. Panel B: direct correlation between Migration Index and CCR7 expression on pDC. Panel C: inverse correlation
between Migration Index and pDC frequency in PBMC of HIV-1 patients. Panel D: direct correlation between Migration Index and HIV-1 viremia.
Closed circles (N): viremic patients; closed diamonds (X): aviremic patients.
doi:10.1371/journal.pone.0011110.g003
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believe that the freezing-thawing process influenced, skewed or
altered our studies in a way to lead to ‘‘artifactual’’ results.
Concurrently, we found that pDC in peripheral blood of HIV-1
patients express significantly higher levels of the lymph node
homing markers, CCR7 and CD62L. Indeed, we showed that
pDC of viremic HIV-1 patients responded more potently to
CCR7 ligands – CCL19 and CCL21 – in ex vivo migration assays
under conditions that minimize cell differentiation. Altogether,
these results provide a mechanism for the accumulation of pDC in
LN. We found a strong correlation between HIV-1 viremia,
CCR7 expression, lower frequency in PBMC, and migratory
potential in ex vivo assays. Indeed, exposure of pDC to infectious or
noninfectious HIV-1 particles in vitro leads to upregulation of
functional CCR7 [52]. Moreover, previous studies by Desai et al.
and by Dillon et al. failed to observe an up-regulation of CCR7 on
circulating pDC of HIV-1 patients [38,53]. The inconsistency
between our findings and those of those two studies may be due to
a number of factors. For instance, Desai et al. focused their analysis
on pediatric patients under therapy, while our study involved adult
patients most of which were not undergoing ART. On the other
hand, Dillon et al. used mean fluorescence intensity (MFI) to
analyze CCR7 expression, while our study employed geometric
mean fluorescence intensity (GMFI). Since CCR7 expression does
not follow a normal distribution, and since its expression has a
dynamic range of 2-3 logs, GMFI gives a more accurate estimate
of the central tendency in the data sets than MFI. This conclusion
is also supported by our functional studies, which showed that
pDC of viremic HIV-1 patients display increased migratory
potential in in vitro assays. Therefore, our studies are the first to
demonstrate that the decline of pDC in peripheral blood of
asymptomatic HIV-1 patients does not simply reflect a systemic
cell loss, but rather can be explained – at least in part – with
redistribution to peripheral lymph nodes in response to viral
replication. Our results reflect closely the situation observed in
pathogenic SIV infection of non-natural hosts. Several studies
showed a sharp decline of circulating pDC during the acute phase
of SIV infection in macaques, which persists throughout the
infection [33,34,54,55]. Concurrently, pDC were found at higher
Figure 4. Activated but immature phenotype of lymph node-homed pDC from HIV-1 positive versus negative individuals. Panel A:
identification of pDC populations in LNMC of a representative control (top panel) and HIV-1 positive (bottom panel) individual. LNMC were stained
with anti-BDCA2 and anti-CD123 antibodies; analyses were carried out by gating on the live cell population as determined by forward and side
scatter light profiles. Panels B, D, F and H: flow cytometry plots showing expression levels of activation (CD40 and BDCA2) and maturation (CD83 and
CD86) markers on lymph node-homed pDC from a representative HIV-1 patient and control individual. Histogram plots were obtained by gating onto
the live cell population as assessed by forward and side light scatter profile (not shown), and then onto the pDC population as identified by staining
with anti-BDCA2 and anti-CD123 antibodies (as shown in density plots). Gray area: healthy control; black line: HIV-1 patient. Panels C, E, G, and I:
expression levels of CD40, BDCA2, CD83 and CD86 on lymph node-homed pDC of control individuals (black bars; n=11) and HIV-1 patients (white
bars; n=18). We assessed the Geometric Mean Fluorescence Intensity (GMFI) values for each marker (Materials and Methods). Panels show the Mean
and SEM of the GMFI values determined with cells from all individuals in the two study groups.
doi:10.1371/journal.pone.0011110.g004
Table 4. Features of lymph node-homed pDC.
Feature Marker
HIV-1 positive
(n=18)
Controls
(n=11)
p
values
Activation CD40 26.263.5 7.861.3 ,0.0001
BDCA2 206.2620.8 462.5685.9 ,0.03
Maturation CD83 99.7626.5 77.8634.6 .0.05
CD86 14.762.4 9.962.3 .0.05
Function IFNa 66.7611.3 40.068.9 ,0.01
Death Annexin V 15.561.5 8.961.9 =0.01
Data are Mean 6 Standard Error of Means of the Geometric Mean Fluorescence
Intensity (GMFI) values determined for all individuals in each study group. For
Annexin V, data are Mean 6 Standard Error of the percent Annexin V positive
values determined for all individuals in each study group.
doi:10.1371/journal.pone.0011110.t004
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the onset of AIDS through a mechanism involving apoptosis [33].
The acute phase of non-pathogenic SIV infection in natural hosts
(e.g. sooty mangabeys and African green monkeys) also involves a
decline of circulating pDC, which initially relocate to lymph
nodes, and then return to the circulation following the onset of the
chronic phase [35]. Therefore, pDC dynamics sharply discrimi-
nate pathogenic and non-pathogenic lentiviral infection in humans
and animal models. Our studies also found that circulating pDC of
HIV-1 patients express higher levels of CD103 (also known as
integrin aE), which – in complex with integrin b7 – mediates cell
redistribution to the intraepithelial sites and lamina propria of the
GALT. Evidence of higher levels of CD103 on pDC of HIV-1
patients may also indicate relocation of these cells to lymphoid
tissues lining the gut mucosa. This hypothesis will be addressed in
future studies.
In this report we also assessed the activation, maturation and
function of pDC in lymph nodes of HIV-1 patients compared to
healthy controls. Our results demonstrate that pDC in LN of
HIV-1 donors display an altered cell surface expression profile
of activation/maturation markers with higher CD40, lower
BDCA2, and stable CD83 and CD86 levels. A previous report
Figure 5. Increased IFNa expression by pDC in lymph nodes of HIV-1 patients. Panel A: flow cytometry plot showing expression of IFNa by
lymph node-homed pDC from a representative healthy control and an HIV-1 patient. Histogram plot was obtained by gating onto the live cell
population as assessed by forward and side light scatter profile (not shown), and then onto the pDC population as identified by staining with anti-
BDCA2 and anti-CD123 antibodies. Top density plot and gray area histogram: healthy control; bottom density plot and black line histogram: HIV-1
patient. Panel B: summary results for expression levels of IFNa by lymph node-homed pDC of healthy controls (black bar; n=11) and HIV-1 patients
(white bar; n=18). We assessed the Geometric Mean Fluorescence Intensity (GMFI) value with cells from all individuals in the two study groups
(Materials and Methods). Panel shows the Mean and SEM of the GMFI values.
doi:10.1371/journal.pone.0011110.g005
Figure 6. Higher rates of cell death by pDC in lymph nodes of HIV-1 patients. Panel A: flow cytometry plot showing Annexin V staining of
lymph node-homed pDC from a representative HIV-1 patient and control individual. Histogram plots were obtained by gating onto the live cell
population as assessed by forward and side light scatter profile (not shown), and then onto the pDC population as identified by staining with anti-
BDCA2 and anti-CD123 antibodies. Top density plot and gray area histogram: healthy control; bottom density plot and black line histogram: HIV-1
patient. Panel B: summary results for expression levels of Annexin V by lymph node-homed pDC of healthy controls (black bar; n=11) and HIV-1
patients (white bar; n=18). We determined the percentage of Annexin V positive pDC from all individuals in the two study groups (Materials and
Methods). Panel shows the Mean and SEM values of the percent Annexin V positive pDC.
doi:10.1371/journal.pone.0011110.g006
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1p a t i e n t sa l s oe x p r e s sh i g h e rC D 4 0a n dl o w e rC D 8 6l e v e l s
[56]. In addition, that study found a higher percentage of IFNa-
expressing cells in lymph nodes of HIV-1 positive individuals.
The decline in BDCA2 expression on pDC of HIV-1 patients is
relevant for multiple reasons [57]. First, BDCA2 is a class II C-
type lectin involved in antigen capture and presentation [50,58].
Second, pDC stimulated through BDCA2 promote CD4
+ Tc e l l
proliferation and differentiation toward Th1 effector cells [59].
Third, BDCA2 stimulation leads to decreased IFNa expression
by pDC [58]. Thus, lower BDCA2 levels on pDC of HIV-1
patients are consistent with the notion that these cells have
reduced capacity to function as antigen presenting cells and to
stimulate CD4
+ T cell proliferation, while retaining the ability
to express IFNa. Indeed, we demonstrated that pDC from LN
of HIV-1 patients secrete higher amounts of IFNa by using a
flow cytometry-based assay in the absence of exogenous stimuli
that may yield artifactual results [47]. Also, our previous studies
showed that IFNa expression by circulating pDC was increased
in HIV-1 patients both at the RNA and protein level, but did
not correlate with HIV-1 viral load in blood [28,30]. A recent
study also showed that pDC of women express more IFNa than
pDC of men [60]. Since in our study the cohort of HIV-1
positive lymph node donors included only men, it is possible
that a cohort including both men and women would have
e v i d e n c e da ne v e nm o r ed r a m a t i ci n c r e a s ei nI F N a expression
by lymph node-homed pDC during HIV-1 infection. In the
present report, we did not observe any correlation between
IFNa expression by LN-homed pDC and HIV-1 viremia. Thus,
active virus replication appears to lead to higher CCR7
expression and pDC migration to lymph nodes, but not to
higher IFNa expression by lymph node-homed pDC. However,
several studies showed that pDC can be triggered to express
IFNa following exposure to both infectious and non-infectious
HIV-1 as well as by HIV-1 proteins [61,62], suggesting that
viral particles and/or proteins trapped in the intercellular space
of lymph nodes may be involved in promoting IFNa expression
by pDC. Indeed, recent studies found that viral gag proteins
persist on the surface of the FDC network over prolonged
periods of time even during controlled viral replication in the
presence of HAART [63]. Alternatively, this may be the
consequence of events set in motion during HIV-1 infection, but
not sustained by ongoing viral replication. Once again, parallel
studies conducted in pathogenic versus non-pathogenic SIV
models underscore the relevance of our findings in the context
of HIV-1 infection. Indeed, pDC express copious amounts of
IFNa during the acute and chronic phase of SIV infection in
macaques, both in peripheral blood and in lymphoid tissues
[54,64]. By converse, pDC express IFNa in lymph nodes during
the acute phase of SIV infection in the natural host, but IFNa
levels returns to baseline values during the chronic phase of the
non-pathogenic infection [35]. Moreover, the amplitude of the
IFNa response to SIV infection in natural hosts during the acute
phase is reduced compared to non-natural hosts [29,35],
reflecting a lower responsiveness of pDC from natural hosts to
TLR7 and TLR9 stimuli [29].
Persistent activation of the immune system in the face of
impaired immune responses is a hallmark of pathogenic lentiviral
infection, and is a potent predictor of disease progression
[2,3,4,5,6]. By contrast, non-pathogenic SIV infection is
characterized by normal levels of immune activation despite
vigorous viral replication [65]. The mechanism(s) at play in this
phenomenon have been investigated, but remain elusive.
Recently, several studies that bacterial translocation from the
lumen of the gastro-intestinal tract following HIV-1 and SIV-
mediated depletion of CD4
+ T cells in the GALT might be
involved [66]. However, this hypothesis has been questioned
because of the lack of bacterial translocation in non-pathogenic
SIV infection despite CD4
+ T cell depletion in the GALT
[66,67]. Recently, two reports suggested that over-expression of
IFNa may be involved in driving persistent immune activation
during HIV-1 infection. Sedaghat et al. reported that activated
CD4
+ T cells from peripheral blood of untreated HIV-1 patients
are in a hyper-proliferative state under the modulation of IFNa
[31]. In addition, studies by Mandl et al. suggested that
production of IFNa by pDC in SIV-infected non-natural hosts
may drive the chronic immune activation and dysfunction
leading to AIDS [29]. However, neither study addressed the
mechanism underlying this phenomenon.
In summary, we showed that untreated HIV-1 infection is
characterized by elevated expression of CCR7 and CD62L on
plasmacytoid dendritic cells, which relocate to lymph nodes,
acquire an activated but immature phenotype, and express
elevated amounts of IFNa before undergoing cell death. Our
results are in line with other reports suggesting a potential role for
IFNa in promoting chronic immune activation during HIV-1 and
SIV infection. Further studies into this phenomenon may shed
new light on the mechanisms of HIV-1 pathogenesis.
Figure 7. Increased rates of pDC apoptosis correlate with pDC frequency, IFNa expression by LN-homed pDC, and HIV-1 viremia.
Panels A, B and C: direct correlation between intensity of Annexin V staining on LN-homed pDC of HIV-1 patients and their frequency in LNMC, their
ability to express IFNa, and the HIV-1 viral load in peripheral blood, respectively.
doi:10.1371/journal.pone.0011110.g007
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